A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Averted.
<h4>Introduction</h4>Calculating the cost per disability-adjusted life years (DALYs) averted associated with interventions is an increasing popular means of assessing the cost-effectiveness of strategies to improve population health. However, there has been no systematic attempt to chara...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0168512 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849430063142928384 |
|---|---|
| author | Peter J Neumann Teja Thorat Yue Zhong Jordan Anderson Megan Farquhar Mark Salem Eileen Sandberg Cayla J Saret Colby Wilkinson Joshua T Cohen |
| author_facet | Peter J Neumann Teja Thorat Yue Zhong Jordan Anderson Megan Farquhar Mark Salem Eileen Sandberg Cayla J Saret Colby Wilkinson Joshua T Cohen |
| author_sort | Peter J Neumann |
| collection | DOAJ |
| description | <h4>Introduction</h4>Calculating the cost per disability-adjusted life years (DALYs) averted associated with interventions is an increasing popular means of assessing the cost-effectiveness of strategies to improve population health. However, there has been no systematic attempt to characterize the literature and its evolution.<h4>Methods</h4>We conducted a systematic review of cost-effectiveness studies reporting cost-per-DALY averted from 2000 through 2015. We developed the Global Health Cost-Effectiveness Analysis (GHCEA) Registry, a repository of English-language cost-per-DALY averted studies indexed in PubMed. To identify candidate studies, we searched PubMed for articles with titles or abstracts containing the phrases "disability-adjusted" or "DALY". Two reviewers with training in health economics independently reviewed each article selected in our abstract review, gathering information using a standardized data collection form. We summarized descriptive characteristics on study methodology: e.g., intervention type, country of study, study funder, study perspective, along with methodological and reporting practices over two time periods: 2000-2009 and 2010-2015. We analyzed the types of costs included in analyses, the study quality on a scale from 1 (low) to 7 (high), and examined the correlation between diseases researched and the burden of disease in different world regions.<h4>Results</h4>We identified 479 cost-per-DALY averted studies published from 2000 through 2015. Studies from Sub-Saharan Africa comprised the largest portion of published studies. The disease areas most commonly studied were communicable, maternal, neonatal, and nutritional disorders (67%), followed by non-communicable diseases (28%). A high proportion of studies evaluated primary prevention strategies (59%). Pharmaceutical interventions were commonly assessed (32%) followed by immunizations (28%). Adherence to good practices for conducting and reporting cost-effectiveness analysis varied considerably. Studies mainly included formal healthcare sector costs. A large number of the studies in Sub-Saharan Africa addressed high-burden conditions such as HIV/AIDS, tuberculosis, neglected tropical diseases and malaria, and diarrhea, lower respiratory infections, meningitis, and other common infectious diseases.<h4>Conclusion</h4>The Global Health Cost-Effectiveness Analysis Registry reveals a growing and diverse field of cost-per-DALY averted studies. However, study methods and reporting practices have varied substantially. |
| format | Article |
| id | doaj-art-a5b826284e4a4ae7ba9d0c951d698784 |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-a5b826284e4a4ae7ba9d0c951d6987842025-08-20T03:28:09ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-011112e016851210.1371/journal.pone.0168512A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Averted.Peter J NeumannTeja ThoratYue ZhongJordan AndersonMegan FarquharMark SalemEileen SandbergCayla J SaretColby WilkinsonJoshua T Cohen<h4>Introduction</h4>Calculating the cost per disability-adjusted life years (DALYs) averted associated with interventions is an increasing popular means of assessing the cost-effectiveness of strategies to improve population health. However, there has been no systematic attempt to characterize the literature and its evolution.<h4>Methods</h4>We conducted a systematic review of cost-effectiveness studies reporting cost-per-DALY averted from 2000 through 2015. We developed the Global Health Cost-Effectiveness Analysis (GHCEA) Registry, a repository of English-language cost-per-DALY averted studies indexed in PubMed. To identify candidate studies, we searched PubMed for articles with titles or abstracts containing the phrases "disability-adjusted" or "DALY". Two reviewers with training in health economics independently reviewed each article selected in our abstract review, gathering information using a standardized data collection form. We summarized descriptive characteristics on study methodology: e.g., intervention type, country of study, study funder, study perspective, along with methodological and reporting practices over two time periods: 2000-2009 and 2010-2015. We analyzed the types of costs included in analyses, the study quality on a scale from 1 (low) to 7 (high), and examined the correlation between diseases researched and the burden of disease in different world regions.<h4>Results</h4>We identified 479 cost-per-DALY averted studies published from 2000 through 2015. Studies from Sub-Saharan Africa comprised the largest portion of published studies. The disease areas most commonly studied were communicable, maternal, neonatal, and nutritional disorders (67%), followed by non-communicable diseases (28%). A high proportion of studies evaluated primary prevention strategies (59%). Pharmaceutical interventions were commonly assessed (32%) followed by immunizations (28%). Adherence to good practices for conducting and reporting cost-effectiveness analysis varied considerably. Studies mainly included formal healthcare sector costs. A large number of the studies in Sub-Saharan Africa addressed high-burden conditions such as HIV/AIDS, tuberculosis, neglected tropical diseases and malaria, and diarrhea, lower respiratory infections, meningitis, and other common infectious diseases.<h4>Conclusion</h4>The Global Health Cost-Effectiveness Analysis Registry reveals a growing and diverse field of cost-per-DALY averted studies. However, study methods and reporting practices have varied substantially.https://doi.org/10.1371/journal.pone.0168512 |
| spellingShingle | Peter J Neumann Teja Thorat Yue Zhong Jordan Anderson Megan Farquhar Mark Salem Eileen Sandberg Cayla J Saret Colby Wilkinson Joshua T Cohen A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Averted. PLoS ONE |
| title | A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Averted. |
| title_full | A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Averted. |
| title_fullStr | A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Averted. |
| title_full_unstemmed | A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Averted. |
| title_short | A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Averted. |
| title_sort | systematic review of cost effectiveness studies reporting cost per daly averted |
| url | https://doi.org/10.1371/journal.pone.0168512 |
| work_keys_str_mv | AT peterjneumann asystematicreviewofcosteffectivenessstudiesreportingcostperdalyaverted AT tejathorat asystematicreviewofcosteffectivenessstudiesreportingcostperdalyaverted AT yuezhong asystematicreviewofcosteffectivenessstudiesreportingcostperdalyaverted AT jordananderson asystematicreviewofcosteffectivenessstudiesreportingcostperdalyaverted AT meganfarquhar asystematicreviewofcosteffectivenessstudiesreportingcostperdalyaverted AT marksalem asystematicreviewofcosteffectivenessstudiesreportingcostperdalyaverted AT eileensandberg asystematicreviewofcosteffectivenessstudiesreportingcostperdalyaverted AT caylajsaret asystematicreviewofcosteffectivenessstudiesreportingcostperdalyaverted AT colbywilkinson asystematicreviewofcosteffectivenessstudiesreportingcostperdalyaverted AT joshuatcohen asystematicreviewofcosteffectivenessstudiesreportingcostperdalyaverted AT peterjneumann systematicreviewofcosteffectivenessstudiesreportingcostperdalyaverted AT tejathorat systematicreviewofcosteffectivenessstudiesreportingcostperdalyaverted AT yuezhong systematicreviewofcosteffectivenessstudiesreportingcostperdalyaverted AT jordananderson systematicreviewofcosteffectivenessstudiesreportingcostperdalyaverted AT meganfarquhar systematicreviewofcosteffectivenessstudiesreportingcostperdalyaverted AT marksalem systematicreviewofcosteffectivenessstudiesreportingcostperdalyaverted AT eileensandberg systematicreviewofcosteffectivenessstudiesreportingcostperdalyaverted AT caylajsaret systematicreviewofcosteffectivenessstudiesreportingcostperdalyaverted AT colbywilkinson systematicreviewofcosteffectivenessstudiesreportingcostperdalyaverted AT joshuatcohen systematicreviewofcosteffectivenessstudiesreportingcostperdalyaverted |